23 min
Ep 5: Functional & QoL Outcomes in a Sea of Clinical Event Data Heart Failure in Focus
-
- Scienze
This month we are joined by Dr Mikhail Kosiborod, clinical trialist, Professor of Medicine at St Luke’s Heart Institute and leading expert on Quality of Life (QoL) instruments world-wide.
Dr Kosiborod discusses functional and QoL outcomes of foundational therapies in Heart Failure (HF) and the clinical application of this data. Additionally, we learn how scoring systems like the Kansas City Cardiomyopathy Questionnaire (KCCQ) can be used to establish clinically meaningful change in functional status. Finally, we consider how regulators future guideline development might start to look beyond the New York Heart Association (NYHA) classification and embrace QoL and overall health status when assessing HF treatments.
Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO.
This podcast is supported by an unrestricted educational grant from AstraZeneca.
This month we are joined by Dr Mikhail Kosiborod, clinical trialist, Professor of Medicine at St Luke’s Heart Institute and leading expert on Quality of Life (QoL) instruments world-wide.
Dr Kosiborod discusses functional and QoL outcomes of foundational therapies in Heart Failure (HF) and the clinical application of this data. Additionally, we learn how scoring systems like the Kansas City Cardiomyopathy Questionnaire (KCCQ) can be used to establish clinically meaningful change in functional status. Finally, we consider how regulators future guideline development might start to look beyond the New York Heart Association (NYHA) classification and embrace QoL and overall health status when assessing HF treatments.
Questions can be sent via Twitter to our host @mvaduganathan or to @radcliffeCARDIO.
This podcast is supported by an unrestricted educational grant from AstraZeneca.
23 min